The Board of Directors collaborates to provide strategic clarity, direction, and policy objectives for DIA. The Board of Directors and its Standing Committees ensure DIA meets the requirements of our members in the content of our programs, research, and financial decisions.
Board membership is voluntary, and DIA does not compensate Directors or members of Advisory Councils for their contributions.
Chair of DIA Board
Chair of Executive Committee
Dr. Lingshi Tan is Chairman and CEO of dMed-Clinipace, a Global full-service Clinical CRO that aspires to be a next-generation clinical development partner, empowering customers to deliver innovative solutions to patients worldwide, especially in the two largest healthcare markets, the U.S. and China. dMed-Clinipace is resulted in a merger between dMed and Clinipace in April 2021. Prior to founding dMed in Shanghai in 2016, Dr. Tan was Pfizer’s VP of Worldwide Development Operations and Chairman and GM of Pfizer (China) Research & Development Co., Ltd. (CRDC). He was assigned from New York to Shanghai to establish the CRDC in 2005. Under Dr. Tan’s Leadership for 11 years, the CRDC grew to an organization of more than 1,000 professionals and became an integral part of Pfizer’s global R&D network, focusing on clinical development, safety, regulatory, and medical functions.
Rebecca A. Vermeulen
Immediate Past Chair
Chair of Governance Committee
Rebecca Vermeulen, RPh, brings a variety of experiences to her role as VP of Strategy for Patients and Society, Product Development, at Hoffman La Roche. She has served in numerous functions including Medical Affairs, Clinical Research, Sales, Medical Communications, Medical Science Liaisons, Patient Partnership, Digital Health, and Six Sigma, in her 28 years of healthcare industry experience, and has been responsible for creating global standards for information exchange with healthcare professionals and patients. Rebecca is currently Chair of the DIA Board of Directors, Chair of the Healthcare Businesswomen’s Association Corporate Board of Directors, and serves on the Patient Focused Medicine Development Advisory Committee.
Judith Ng-Cashin, MD, is currently the Chief Medical Officer at Eagle Pharmaceuticals, leading R&D across the development pipeline and marketed products. Prior to this role, she served as CMO for AOBiome Therapeutics, leading end-to-end asset development strategy, medical governance, and manufacturing. She also served as Chief Scientific Officer and led the Safety & Pharmacovigilance business unit for Syneos Health. Before Syneos, she spent nearly a decade in R&D for a top five pharmaceutical company. Dr. Ng-Cashin earned her MD from Rush Medical College, trained in Internal Medicine at the University of Chicago, and received an infectious diseases and hematology fellowship training at the University of North Carolina.
Chair of Finance Committee
Michael Romano is a Partner and leader of the Life Sciences Industry practice group for RSM US LLP; he is also a Partner in RSM’s Technology and Management Consulting practice, and leads RSM’s Finance and Accounting Outsourcing group. Michael has more than 25 years of diverse experience in both the life sciences industry and as an audit and business consultant, and has orchestrated successful financial and operational turnarounds, restructured and reorganized businesses, and successfully executed growth strategies in the life sciences industry. He also served as Vice President and General Manager of a global medical publisher offering health information products and services to the pharmaceutical, biotech, and medical device markets.
Barbara Lopez Kunz
President and Global Chief Executive
Barbara Lopez Kunz serves as President and Global Chief Executive of DIA, driving thought leadership and innovation in therapeutic development to improve the health of people worldwide. She previously served as President of Health and Life Sciences at Battelle, one of the world’s largest, most respected R&D organizations. She has also served as Senior Vice President/General Manager for Thermo Fisher Scientific’s Biosciences Division, as SVP for DuPont, and head of R&D for ICI. A dedicated volunteer for children's health, Barbara chairs the board of Children's National Research Institute, serves as advisor to the UC I4H Fellowship, and as Director for Aptevo Therapeutics.
Mike A. B. Devoy
Dr Michael Devoy is the Executive Vice President for Medical Affairs and Pharmacovigilance for the Pharmaceuticals Division at Bayer AG. He is also the Chief
Medical Officer of Bayer AG. Dr Devoy joined the former Schering AG in 2005 as Senior VP of Global Medical Development and was appointed to his current position in 2014. Dr Devoy studied Medicine and Pharmacology at University College London and graduated with a Bachelor of Medicine/Bachelor of Surgery (MB, BS). He is a member of the Royal College of Physicians in London. Dr Devoy has extensive experience across Clinical Development and International Medical Affairs. His career in the pharmaceutical industry began when he joined Glaxo Group Research in Clinical Pharmacology.
Elizabeth Garner has over a decade of pharmaceutical development experience, holding roles of increasing strategic responsibility while developing expertise in clinical trial design and execution, including positions at ObsEva SA, Merck, Abbott (AbbVie), Myriad Genetics, and Agile Therapeutics. She joined ObsEva as CMO in July 2019, and was previously CMO at Agile Therapeutics. Dr. Garner is a member of the Board of Directors of Kezar Life Sciences, Pharm-Olam, and the American Medical Women’s Association. She received joint M.D./M.P.H degrees from Harvard Medical School and Harvard School of Public Health and was trained in ob/gyn and gynecologic oncology at Brigham and Women’s/Massachusetts General Hospital/Dana Farber Cancer Institute.
Chair of Audit Committee
Tatyana Kosheleva, CPA, is currently CFO at Amring Pharmaceuticals Inc. where she is a member of the Executive Board responsible for all aspects of the firm's financial operations. Tatyana has over 20 years of diverse Finance experience ranging from start-ups to Fortune 50 public companies in the life sciences and technology industries across four countries. Tatyana earned her MBA degree in International Management from Thunderbird School of Global Management, a part of the Arizona State University.
Michael Rosenblatt, MD, Chief Medical Officer of Flagship Pioneering, has advanced academic and biopharmaceutical research and development throughout his career. He was previously Chief Medical Officer for Merck, after serving as Dean of Tufts Medical School. Formerly, he was Ebert Professor of Molecular Medicine and Minot Professor at Harvard. He served as President of Beth Israel Deaconess Medical Center and as Director of the Harvard-MIT Division of Health Sciences & Technology. He is on the board of several biotech companies, and on the Harvard Medical School Board of Fellows and research advisory committees of the Massachusetts General, Brigham and Women’s, and Children’s Hospitals. He earned his MD from Harvard Medical School.
Peter Sorger is the Otto Krayer Professor of Systems Pharmacology at Harvard Medical School. He received his AB from Harvard College and PhD from Trinity College, Cambridge University U.K., working under the supervision of Hugh Pelham. He trained as a postdoctoral fellow at the University of California, San Francisco with Harold Varmus and Andrew Murray. Prior to coming to HMS Peter served as a Professor of Biology and Biological Engineering at MIT. Sorger was cofounder of Merrimack Pharmaceuticals and Glencoe Software and is an advisor to multiple public and private companies and research institutes in the US, Europe and Japan.
Dr. Takahashi is currently Director and Chief Operating Officer, BONAC Corporation, a bio-tech venture company in Japan. He graduated from Hokkaido University School of Medicine in 1981, and received his PhD in Medical Science in 1986. He served as Research Assistant Professor of Medicine at Vanderbilt University from 1990 to 1992, and joined Merck Research Laboratories in 1992 and served as Vice President, Merck Research Laboratories from 2003 to 2008. After retiring from Merck, he served as a President & CEO of LOTUS Pharmaceutical Co. Ltd, a bio-venture company. He joined GlaxoSmithKline in 2009 and served as Vice President and Director of Japan Development of GSK Japan before joining BONAC in January 2021.
Cynthia L. Verst
Cynthia L. Verst, PharmD, MS, is President of Design and Delivery Innovation for R&D Solutions at IQVIA, responsible for accelerating growth through innovative solutions powered by rich data assets, advanced predictive analytics, integrated technology capabilities, and deep domain expertise to develop actionable insights that drive better clinical research outcomes. Dr. Verst has been named one of the Top Women in Biotech by FierceBiotech, and was the 2019 Board of Directors’ Chairman of the Association of Clinical Research Organizations. Dr. Verst earned her PharmD and Bachelor’s degree in Pharmacy from the University of Cincinnati, and her Master’s degree in Structural and Cellular Biology from the University of Illinois.
Karin Van Baelen
Karin is leading the Global Regulatory Affairs organization at Janssen. She facilitates the relationship between the Janssen pharmaceutical companies and global health authorities, influencing and interpreting global regulatory requirements and enabling our companies to meet those guidelines. In addition, she oversees the development of regulatory strategy for products from all therapeutic areas. Karin engages in policy development at national and international levels.
Frank Jiang, MD, Ph.D., is Chief Executive Officer and Chairman of the Board of CStone Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development of innovative oncology drugs. Prior to joining CStone Pharmaceuticals, Dr Jiang served as Head of Asia Pacific R&D with Sanofi and built a R&D regional hub encompassing Japan, China and among other 12 countries with 1,400 staff. One of his career highlights at Sanofi was leading a 21,000 patient ‘megatrial’, which resulted in a successful global registration of a blockbuster drug Lovenox. Prior to Sanofi, Dr Jiang served as clinical research physician with Eli Lilly and led a global phase II trial in Sepsis. Dr Jiang is a US board certified physician (internal medicine)